'Report of meeting of the Section of Clinical Immunology & Allergy, 7 November 1983 . Accepted 27 April 1984 size shows that CS-A inhibits T-cell proliferation at a primed state of the cell cycle, not the resting phaseimplying that the cells respond to an initial signal before CS-A exerts its effect.
Clonal expansion of T-cells requires the second stimulus of interleukin-2 (IL-2) acting on primed cells bearing the IL-2 receptor. The evidence is conflicting as to whether IL-2 is produced by Tcells exposed to CS-A, but it seems that an increase in exogenous IL-2 will not overcome the defect induced by CS-A. Despite this, Dr White's experiments suggested that the IL-2 receptor is still expressed by the T-cells after exposure to CS-A.
It would therefore appear that CS-A inhibits Tcell proliferation by some interaction with IL-2 or the receptor for this mediator; however, the lack of purified IL-2 make such experiments difficult.
Professor R Calne (Addenbrooke's Hospital, Cambridge) reiterated that azathioprine and steroids have been used for a considerable time in organ transplantation. Although side effects of this combination can be catastrophic, the therapeutic index had not been bettered until the advent of CS-A in 1977.
Initial work in pigs with cardiac transplants and dogs with renal allografts gave excellent results using CS-A; however, on stopping the drug, rejection usually ensued. This is in contrast to the rodent where a short course of CS-A appeared to induce a tolerant state, allowing maintenance of good cardiac allograft function in the absence of immunosuppression. In patients from Cambridge (Calne et al. 1982 ) and more recently in the European multicentre trial (Wood 1982) , results with cadaveric renal transplants using CS-A showed considerable improvement over control groups taking azathioprine and steroids. As yet, however, tolerance has not been induced in man.
The major adverse effect of CS-A is undoubtedly nephrotoxicity. Serum creatinine levels may rise to more than twice the upper limit of normal but will usually revert after changing therapy. Renal biospy has revealed early interstitial fibrosis both in a few patients with cardiac transplants and in renal transplant patients, suggesting that this effect can be caused by CS-A rather than complications of renal transplantation (Hamilton et al. 1982) . Patient acceptability of CS-A is high, and this drug has enabled renal transplantation to be carried out in children without the need for long-term steroids.
The excellent results with CS-A in kidney transplants have also been seen in transplantation of the heart, liver, and pancreas, although at 8o 1984 The Royal Society of Medicine 0 1 41-0768i'84/080701-03,/$O 1.00/0 Addenbrooke's azathioprine and steroids are given to the liver cases during the early postoperative phase, as CS-A is poorly absorbed in the absence of bile. In 1982 Starzl et al. reported a doubling of the one-year survival in liver transplants; they used CS-A in conjunction with steroids although so far there is no evidence of synergy.
Dr R Powles (Royal Marsden Hospital, Sutton) reported success in matched bone marrow transplants using CS-A. Acute graftversus-host disease is now responsible for death in only 5% of cases, and if transplants are performed during first remission of acute myeloblastic leukaemia, the predicted survival is 60% at five years (Powles & Morgenstern 1982) . This improvement is attributable to CS-A but is reversible, as after withdrawal at six months graft-versus-host disease may recur and necessitate reinstatement of CS-A therapy. Difficulty has been noted in finding fully-matched donors at all four HLA loci, so recently grafts have been used from family relatives with only one HLA locus identical to the patient.
Mismatched transplants performed during first remission of acute myeloblastic leukaemia have a good prognosis if the patients are under 30, but disastrous results for those who are older. Early death occurs from what appears to be an increase in general vascular permeability, with pulmonary and cerebral oedema complicated by pneumonia, convulsions and renal failurea picture not unlike haemolytic uraemic syndrome.
In the completely-matched transplants this problem also occurs but only in approximately 20% of cases. Nephrotoxicity, hepatoxicity or other side effects of CS-A occur during these episodes, and may necessitate stopping the drug altogether. When analysed according to dosage of CS-A, it was found that 30% of patients had no dose change and in this group 91 % are alive and well. However, if the CS-A dosage was reduced (24% of cases), usually because of nephrotoxicity, then mortality rose to 55%. The latter group of patients are the more severely ill group as judged by an increased duration of aminoglycoside administration, and more generally by a higher number of pyrexial days.
The postulated abnormality that develops in this group of patients is one of vascular change from host endothelium to a chimaera of host and donor tissue. The abnormality occurs about one week after transplantation, and may represent a sensitization to CS-A which occurs before the kidney or liver damage.
Hepatotoxicity manifests itself by an elevation of serum liver enzymes and bilirubin. In a few cases the latter rises to above 1000 mg/litre, and the cause of death in these patients is the generalized increase in vascular permeability and its complications. In some cases bilirubin staining of the brain is noted at post-mortem examination, suggesting a breakdown in the blood-brain barrier. This may allow drugs not normally toxic to the central nervous system to cross in potentially damaging doses, which may further complicate an already difficult situation.
Dr A Weetman (Welsh National School of Medicine, Cardifi) presented data on the use of CS-A in autoimmune thyroid disease. He discussed the model of Hashimoto's thyroiditis produced by neonatal thymectomy followed by sublethal irradiation in the PVG/c strain of rat ). The autoantibody titre against thyroglobulin rose with time, and was associated with lymphocytic infiltration of the thyroid. This occurred in conjunction with an elevation of serum TSH levels, and a subsequent increase in thyroid gland weight. If CS-A was given before the autoantibody titre rose, then maintenance of the normal status quo was observed as assessed by any of* the above parameters. Interestingly, the disease progressed if the drug was stopped, again demonstrating the reversibility of action.
Although CS-A has not been advocated for therapy in Hashimoto's thyroiditis or Graves' disease, an infrequent complication of thyroid disease that has warranted immunosuppression is ophthalmopathy. This complication, although usually associated with Graves' disease, may occur in the absence of hyperthyroidism, and can result in severe visual complicationseven blindness. In the past, steroids, azathioprine and cyclophosphamide have proved of little benefit. A progress report on the use of CS-A in this condition was given at this meeting . Although only 5 patients are at present under study (reflecting the rarity of the condition), all have reported subjective improvements in their eye symptoms, and most have shown improved tests of visual acuity, function or thyroid status. The one patient who deteriorated on CS-A had been on long-term steroids prior to starting the trial, and these were stopped when CS-A was introduced. Interestingly she developed an atypical pneumonia which responded well to therapy and removal of immunosuppression, whilst her eyes continued to show improvement.
Little doubt exists that genetic engineering will help by producing pure chemicals with which to elucidate the specific action of CS-A and other drugs on the immune system. Nonetheless, results in organ-specific autoimmune disease suggest that CS-A is going to be beneficial not only in the transplantation field but also across the board in other immune-system-related disorders, as in the eye (Nassenblatt et al. 1983 ). Indeed if a tolerant state similar to that observed in rodents could be obtained in man, the therapeutic implication for the agent will be very impressive.
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Coloproctology teaching day at Southampton1
For this fourth 'teaching day' of the Section of Colo-Proctology, held in the academic block of Southampton General Hospital, some 50 delegates made their way to the south coast from as far afield as Manchester, Wales, West Germany and Belgium. Travel by train was recommended, a most comfortable and relaxing trip on one of the hourly expresses where bacon and eggs are still served. We were met at 9.30 am by Professor I Taylor, given a conference 'survival kit' by one of the sponsors, containing an antacid and pain relievers, and invited to complete a quiz. There were 30 questions, each with a very brief clinical clue and accompanying X-ray photographs or histology slides. The plan of the day was to take a broad topic for each of 3 sessions, invite speakers to talk about specific problems, and then have frank discussion from all ranks. There were no practical demonstrations of operating methods this time.
The first topic, 'Improving outcome in colorectal surgery', was chaired by the Section President Mr Peter Lord. Four papers were presented, the first on 'Bowel preparation' by Mr P McDonald of Southampton. He outlined the historical approach to the clearing out of the bowel, attempts at which only began seriously this century. Mechanical preparation by enemas, whole gut irrigation, washouts, etc., can clean the bowel but there are risks. The reduction of microorganisms is now the other prime aim. Elemental diets may reduce the bacterial content; antibiotics will be most effective for this purpose. The discussion centred on the best methods and practicality of achieving these desirable results. As might be expected there is no 'best' method recommended as yet. A skilled nursing sister is essential for an adequate whole bowel preparation, and if it fails an 'on table' washout can be done.
Mr S J Karran from Southampton then gave the second paper on the subject of 'Perioperative antibiotics', which although it has a shorter history is becoming overwhelming in the choice of agents available. He dwelt on the role of the surgeon and the environment in the risk factors of sepsis. A large literature exists on the topic and because of the difficulty in designing adequate trials there is again little agreement on a specific patient regimen.
The third paper was concerned with the actual anastomosis following restorative resection of the colon and rectum. Mr F P McGinn from Southampton nailed his colours to the mast when he discussed 'Hand-suture technique'. He uses a ' Report of meeting of the Section of Colo-Proctology, 9 March 1984. Accepted 9 May 1984
